Chondroitin sulfate was superior to placebo and proved equivalent to celecoxib for osteoarthritis of the knee.
SoluMatrix indomethacin may represent a treatment option for the management of moderate acute pain, including patients in emergency room settings.
Data shows that chondroitin sulfate was superior to celecoxib in delaying the progression of knee osteoarthritis.
Celecoxib is comparable to naproxen and ibuprofen in cardiovascular safety for patients with arthritis at high risk for cardiovascular disease.
Clinical Pain Advisor Articles
- Chronic Pain May Be a Contributing Factor to Suicide
- Striking a Balance Between Opioid Surveillance and Patient Privacy
- Demographic Characteristics of Pregnant Women With Opioid Use Disorder
- Supervised Injection Sites: Facts, Information, Pros, and Cons
- Effects of Mindfulness Therapy, Pharmacologic Prophylaxis on Catecholamine Levels in Migraine
- Perioperative Pain Management in Patients With Opioid Use Disorder
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Reviewing the Efficacy of Intrathecal Morphine, Ziconotide for Cancer- and Noncancer Chronic Pain
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Factors Associated With Suboptimal Interscalene Brachial Plexus Block for Arthroscopy
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- Scholarship Support Limited for Veterans Enrolling in MD Programs
- Alpha and Beta Band Activity in MS-Related Chronic Pain
- New Opioid-Induced Constipation Management Guidelines Available